![]() |
|
|
Vol. 291, Issue 3, 1324-1336, December 1999
Department of Pharmacology, Columbia University, New York, New York
Azimilide (AZ) is a class III antiarrhythmic drug that has
voltage-dependent dual effects on the HERG channel: 1) increasing current amplitude at low-voltage depolarization (agonist effect), and
2) suppressing current at more depolarized voltages (antagonist effect). We examined the mechanism for the agonist effect of AZ on HERG
expressed in Xenopus oocytes. The agonist effect
resulted from an AZ-induced `prepulse potentiation: a strong
depolarization prepulse increased the rate and degree of channel
activation induced by subsequent depolarization to
50 or
40 mV. The
potentiated state decayed slowly in an exponential fashion (time
constant, 60-80 s). Degrees of potentiation were proportional
to degrees of channel activation during prepulses; hence, the agonist
effect of AZ was use dependent. AZ exerted its agonist effect from
outside the cell membrane, and the effect did not depend on
intracellular G-protein or protein kinase activity. Mutations made in
the outer mouth or an extracellular loop connecting the S5 and P
regions of HERG, which could hinder or modify conformational
changes in the pore region during membrane depolarization, reduced or
abolished AZ-induced prepulse potentiation. Importantly, these same
mutations also increased the rate and degree of channel activation in
the negative voltage range, and the degree of change in the activation properties was inversely correlated with the degree of AZ-induced prepulse potentiation. We propose that conformational changes in the
outer mouth and neighboring extracellular domain of HERG during
membrane depolarization can affect the process of channel activation.
In the presence of AZ, channel activation allowed drug modification of
these conformational changes, which subsequently facilitated HERG
activation by low-voltage depolarization.
This article has been cited by other articles:
![]() |
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon Pharmacology of cardiac potassium channels Cardiovasc Res, April 1, 2004; 62(1): 9 - 33. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Thomas, W. Zhang, K. Wu, A.-B. Wimmer, B. Gut, G. Wendt-Nordahl, S. Kathofer, V. A.W. Kreye, H. A. Katus, W. Schoels, et al. Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein Cardiovasc Res, July 1, 2003; 59(1): 14 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. A. Volberg, B. J. Koci, W. Su, J. Lin, and J. Zhou Blockade of Human Cardiac Potassium Channel Human Ether-a-go-go-Related Gene (HERG) by Macrolide Antibiotics J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 320 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Caballero, E. Delpón, C. Valenzuela, M. Longobardo, T. González, and J. Tamargo Direct Effects of Candesartan and Eprosartan on Human Cloned Potassium Channels Involved in Cardiac Repolarization Mol. Pharmacol., April 1, 2001; 59(4): 825 - 836. [Abstract] [Full Text] |
||||
![]() |
B. D Walker, C. B Singleton, H. Tie, J. A Bursill, K. R Wyse, S. M Valenzuela, S. N Breit, and T. J Campbell Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel Cardiovasc Res, October 1, 2000; 48(1): 44 - 58. [Abstract] [Full Text] [PDF] |
||||